Search Results

Cantor Fitzgerald analyst Olivia Brayer found supplementary bone mineral density data for Amgen’s obesity candidate MariTide that could point to a potentially greater fracture risk than previously revealed, but some other analysts view the findings as a nonissue.

At six months post-grafting surgery with NVDX3, x-rays demonstrate that 90% of patients have reached, or are steadily progressing towards, complete bone healing Derived from Novadip’s 3M3 stem cell platform, NVDX3, a unique ‘off-the-shelf allogeneic matrix product to cure common but challenging orthopedic conditions, has potential to replace existing allogeneic bone substitutes to heal fractures

Bone Biologics Corporation announces that the first two patients have been treated in the multicenter, prospective, randomized pilot clinical study of the Company’s NB1 bone graft device.

BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced the presentation of new data from an investigator-led analysis of the Phase 2 111-205 study, which demonstrate that children with achondroplasia treated with VOXZOGO® experienced increases in bone length while maintaining bone strength.

Biogennix, an osteobiologics company specializing in products for bone graft procedures, has announced the publication of a detailed scientific study characterizing multiple advanced properties of its TrelCor bone graft material.

ClearPoint Neuro, Inc. today announced it has received 510(k) clearance for its Prism Bone Anchor Accessory.

Inozyme Pharma, Inc. announced a data presentation and sponsored symposium at the 11th International Conference on Children’s Bone Health, which is being held June 22-25, 2024, in Salzburg, Austria.

SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced that the company will be participating in the upcoming 2024 Truist Securities MedTech Conference in Boston.